Polynovo Ltd CALZF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.31
- Day Range
- $1.35–1.35
- 52-Week Range
- $0.40–1.54
- Bid/Ask
- $1.25 / $1.42
- Market Cap
- $931.81 Mil
- Volume/Avg
- 1,000 / 2,781
Key Statistics
- Price/Earnings (Normalized)
- 243.63
- Price/Sales
- 17.09
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 8
- Website
- https://www.polynovo.com
Competitors
Valuation
|
Metric
|
CALZF
|
AVH
|
FPH
|
|---|---|---|---|
Price/Earnings (Normalized) | 243.63 | — | 57.81 |
Price/Book Value | 19.81 | 4.57 | 8.82 |
Price/Sales | 17.09 | 4.39 | 9.07 |
Price/Cash Flow | — | — | 39.48 |
Price/Earnings
CALZF
AVH
FPH
Financial Strength
|
Metric
|
CALZF
|
AVH
|
FPH
|
|---|---|---|---|
Quick Ratio | 4.51 | 7.35 | 1.06 |
Current Ratio | 5.01 | 7.88 | 2.54 |
Interest Coverage | −1.25 | −30.10 | 25.77 |
Quick Ratio
CALZF
AVH
FPH
Profitability
|
Metric
|
CALZF
|
AVH
|
FPH
|
|---|---|---|---|
Return on Assets (Normalized) | 6.00% | −37.61% | 12.48% |
Return on Equity (Normalized) | 8.49% | −50.88% | 16.75% |
Return on Invested Capital (Normalized) | 6.01% | −44.09% | 15.46% |
Return on Assets
CALZF
AVH
FPH
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Mwjmvbkm | Yjdvg | $185.4 Bil | |
SYK
| Stryker Corp | Dbbzwssvm | Spbw | $128.2 Bil | |
BSX
| Boston Scientific Corp | Qrqdstpm | Fhyvnnh | $107.7 Bil | |
MDT
| Medtronic PLC | Jtfkwxj | Rcrcxb | $105.2 Bil | |
DXCM
| DexCom Inc | Tfwwrvdyr | Sfdbk | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Mjgbcmfwt | Pxgktf | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Ryfwgqqstf | Mdmm | $24.6 Bil | |
ALGN
| Align Technology Inc | Lwfdpzbk | Cbzfh | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Gycqfmb | Wvtxtk | $18.7 Bil | |
PODD
| Insulet Corp | Fspmtckyfp | Gtdhjq | $11.5 Bil |